Literature DB >> 9886189

Serum procalcitonin levels in severe Plasmodium falciparum malaria.

U Hollenstein1, S Looareesuwan, A Aichelburg, F Thalhammer, B Stoiser, S Amradee, S Chullawichit, I El Menyawi, H Burgmann.   

Abstract

Levels of procalcitonin (ProCT) have been found to be elevated in individuals with severe bacterial infections such as sepsis and peritonitis, and this correlates well with the severity of the disease. Recently, increased levels have been described in melioidosis and Plasmodium falciparum malaria. In this study ProCT levels were measured in 27 Thai patients with complicated malaria before and during/after treatment with artesunate and mefloquine. Initial parasite counts averaged 290,680/microl (range = 533-1,147,040). On admission, ProCT levels were elevated in all but one patient (median = 40 ng/ml, range = 0.04-662, normal values < 0.5 ng/ml). With treatment, levels decreased to 1.3 ng/ml (range = 0.01-6.5). Nitrite/nitrate levels in patients were higher than in controls throughout the study. The ProCT levels correlated with initial parasite density (P < 0.05), which is a marker of disease severity, and with nitrite/nitrate levels (P < 0.05). Based on the changes of ProCT levels over the course of the disease a possible role in the acute-phase reaction seems likely.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886189     DOI: 10.4269/ajtmh.1998.59.860

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

Review 1.  Procalcitonin: present and future.

Authors:  H H Liu; J B Guo; Y Geng; L Su
Journal:  Ir J Med Sci       Date:  2015-07-10       Impact factor: 1.568

2.  Imported falciparum malaria in adults: host- and parasite-related factors associated with severity. The French prospective multicenter PALUREA cohort study.

Authors:  Fabrice Bruneel; Florence Tubach; Jean-Paul Mira; Sandrine Houze; Sebastien Gibot; Marie-Genevieve Huisse; Bruno Megarbane; Christophe Choquet; Philippe Corne; Eric Peytel; Daniel Villers; Christophe Camus; Olivier Bouchaud; Eric Caumes; Pierre-Marie Girard; Fabrice Simon; Antoine Kalloumeh; Carine Roy; Remy Durand; Jacques Le Bras; Sophie Matheron; Michel Wolff
Journal:  Intensive Care Med       Date:  2016-05-11       Impact factor: 17.440

3.  Nitric oxide is involved in the upregulation of IFN-γ and IL-10 mRNA expression by CD8⁺ T cells during the blood stages of P. chabaudi AS infection in CBA/Ca mice.

Authors:  M Legorreta-Herrera; S Rivas-Contreras; Jl Ventura-Gallegos; A Zentella-Dehesa
Journal:  Int J Biol Sci       Date:  2011-11-01       Impact factor: 6.580

4.  Procalcitonin levels in children affected by severe malaria compared to those with uncomplicated malaria in the absence of bacterial infection: a cross-sectional study.

Authors:  Jean-Claude Katte; Kiya Penanje; Batakeh B Agoons; Eric Noel Djahmeni; Sharon Mbacham-Ngwafor; Vicky Jocelyne Ama Moor; Paul Koki; Wilfred Mbacham
Journal:  Trop Dis Travel Med Vaccines       Date:  2022-03-15

5.  Procalcitonin as a Candidate Biomarker for Malarial Infection and Severe Malaria: A Meta-Analysis.

Authors:  Aongart Mahittikorn; Kwuntida Uthaisar Kotepui; Wanida Mala; Polrat Wilairatana; Manas Kotepui
Journal:  Int J Environ Res Public Health       Date:  2022-09-09       Impact factor: 4.614

6.  Procalcitonin as a biomarker for severe Plasmodium falciparum disease: a critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria.

Authors:  Dennis A Hesselink; Jan-Steven Burgerhart; Hanna Bosmans-Timmerarends; Pieter Petit; Perry J J van Genderen
Journal:  Malar J       Date:  2009-09-01       Impact factor: 2.979

7.  Procalcitonin serum levels in tertian malaria.

Authors:  Christoph Manegold; Stefan Schmiedel; Collins B Chiwakata; Manfred Dietrich
Journal:  Malar J       Date:  2003-10-16       Impact factor: 2.979

8.  Procalcitonin in severe acute respiratory syndrome (SARS).

Authors:  Ai Ping Chua; Kang Hoe Lee
Journal:  J Infect       Date:  2004-05       Impact factor: 6.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.